Evidence map›Paper›PMID 42573183›Full record

Observational studyInvestigative ophthalmology & visual science2026

Defining a Novel RPGR Phenotype of Sector Retinitis Pigmentosa With Cone Dystrophy.

Maram E A Abdalla Elsayed, Omar A Mahroo, Andrew Webster, Stephen H Tsang, João Pedro Marques, Elias Traboulsi, Tien-En Tan, Camiel J F Boon, Cristina Martinez-Fernandez de la Camara, Beau J Fenner and 3 more

Abstract readMulticenter StudyObservational Study
In one paragraph

Observational study in Investigative ophthalmology & visual science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Maram E A Abdalla ElsayedOxford Eye Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.
Omar A MahrooNIHR Biomedical Research Centre at Moorfields Eye Hospital and the UCL Institute of Ophthalmology, London, United Kingdom.
Andrew WebsterNIHR Biomedical Research Centre at Moorfields Eye Hospital and the UCL Institute of Ophthalmology, London, United Kingdom.
Stephen H TsangEdward S. Harkness Eye Institute, Department of Ophthalmology, Columbia University Irving Medical Center/New York-Presbyterian Hospital, New York, New York, United States.
João Pedro MarquesOphthalmology Department, Hospitais da Universidade de Coimbra, Unidade Local de Saúde de Coimbra, Coimbra, Portugal.
Elias TraboulsiCole Eye Institute, Cleveland Clinic, Cleveland, Ohio, United States.
Tien-En TanOxford Eye Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.
Camiel J F BoonDepartment of Ophthalmology, Amsterdam University Medical Centre, Amsterdam, the Netherlands.
Cristina Martinez-Fernandez de la CamaraOxford Eye Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.
Beau J FennerSingapore Eye Research Institute, Singapore National Eye Centre, Singapore, Singapore.
Vincenzo BaroneOphthalmology Complex Operative Unit, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy.
Hélène DollfusERN-EYE Centre de Référence Pour les Affections Rares en Génétique Ophtalmologique, Institut de Génétique Médicale d'Alsace, FSMR SENSGENE, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
Robert E MacLarenOxford Eye Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: RPGRORF15-associated retinal degeneration is characterized by clinical and genetic heterogeneity: Proximal mutations typically result in rod-cone dystrophy, distal mutations in cone-dominated disease, and mutations within open-reading frame 15 (ORF15) in either phenotype. This study characterizes an intermediate phenotype in which patients exhibit a combination of cone dystrophy and incomplete (sectoral) rod-cone dystrophy associated with mutations in the ORF15 region and explores potential mechanistic explanations. Methods: A multinational, multicenter, observational, cross-sectional case series was conducted using databases from RPGR-related retinal dystrophy clinical trial referral centers. Patients with molecularly confirmed RPGR-related cone dystrophy or RPGR-related cone-rod dystrophy were studied. Individuals exhibiting a mixed phenotype of cone dystrophy and sectoral retinitis pigmentosa were identified. In silico analyses assessed the impact of identified mutations on RPGR transcript expression and protein structure. Results: Fourteen patients exhibited a cone dystrophy phenotype with bilateral, symmetrical regions of outer retinal atrophy distributed along the inferior vascular arcades and extending nasally. All harbored ORF15 mutations within a defined transitional zone. All of the mutations were predicted to produce truncated proteins with partial or complete loss of function. Additionally, several were predicted to disrupt splicing regulatory elements. Conclusions: An intermediate phenotype consisting of a cone dystrophy with sectoral retinitis pigmentosa development was characterized. These patients may benefit from full-length RPGR gene therapy. Furthermore, we demonstrate that this rare presentation closely resembles the phenotype observed in some patients with loss-of-function TTLL5-associated cone dystrophy with sectoral involvement.

Indexed as

Cone DystrophyCone-Rod DystrophiesEye ProteinsMutationRetinitis PigmentosaAdultCross-Sectional StudiesDNA Mutational AnalysisElectroretinographyFemaleHumansMaleMiddle AgedPhenotypeYoung AdultEye ProteinsRPGR protein, human

Identifiers

PMID42573183
PMCPMC13480021

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.